–
—
The active ingredient ruxolitinib from Novartis does not work against Covid. In one study, the incidence of severe complications was similar to that of patients who had only received a placebo.
–
Zurich – Setback for the Swiss pharmaceutical company: In a phase III study, the active ingredient ruxolitinib missed the main target in hospitalized Covid patients.
Serious complications, respiratory arrest or admission to the intensive care unit had a similar frequency as patients who had only received a placebo.
The results would not affect ongoing studies for ruxolitinib for the treatment of other diseases.
– .
